20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Down 38.3% in July

20/20 Biolabs Inc (NASDAQ:AIDX) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 153,293 shares, a drop of 38.3% from the July 15th total of 248,647 shares. Currently, 1.8% of the shares of the company are sold short. Based on an average trading volume of 118,274 shares, the short-interest ratio is currently 1.3 days.

20/20 Biolabs Trading Down 1.5%

Shares of AIDX stock opened at $0.51 on Thursday. The stock’s fifty day simple moving average is $0.55. The company has a market cap of $6.49 million and a P/E ratio of -1.82. 20/20 Biolabs has a twelve month low of $0.40 and a twelve month high of $50.00.

20/20 Biolabs (NASDAQ:AIDX) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.26) EPS for the quarter. The firm had revenue of $0.73 million during the quarter.

Wall Street Analyst Weigh In

AIDX has been the topic of a number of research analyst reports. Maxim Group assumed coverage on shares of 20/20 Biolabs in a research note on Monday, May 11th. They issued a “buy” rating and a $5.00 target price on the stock. Weiss Ratings raised 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, 20/20 Biolabs presently has an average rating of “Hold” and an average target price of $5.00.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.